Management tactics for patients with osteoarthritis: a joint view of a rheumatologist and an orthopedic traumatologist

Osteoarthritis is a common disease and occupies the leading place in the number of cases of disability in the world. The pathogenesis of this topical nosology is actively condemned, and researchers have offered a lot of evidence for the leading role of inflammation in the pathogenesis of osteoarthritis, which, by stimulating internal catabolic reactions of chondrocytes, leads to inflammation of the synovial membrane and, as a result, the occurrence of joint pain. Osteoarthritis is the disease with the highest incidence of comorbidities, which complicates the choice of medications for its treatment. And, despite the variety of recommendations, the issue of treating patients with OA remains complex. Based on the recommendations of ESCEO, which were updated in 2019, it is necessary to follow a step-by-step tactic, according to which the introduction of hyaluronic acid preparations intra-articularly is recommended at the 2nd stage of therapy as part of advanced pharmacological correction. Intra-articular hyaluronic acid injection is an alternative local treatment option that provides symptomatic benefit without systemic adverse events. The clinical example demonstrates the experience of joint decision-making on the tactics of managing a patient with persistent OA and the ineffectiveness of therapy at the previous stages. Preference was given to the preparation with high-molecular hyaluronic acid, in the production of which no cross-linking agents were used, due to its effectiveness and safety. A good analgesic and symptom modifying effect of the drug was demonstrated with the result remaining for 6 months. The authors believe that in patients with high comorbidity, drugs for intra-articular administration of hyaluronic acid can take a worthy place in the treatment of osteoarthritis.

1. Cross M., Smith E., Hoy D., Nolte S., Ackerman I., Fransen M. et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-1330. doi: 10.1136/annrheumdis-2013-204763.

2. Musumeci G., Aiello F.C., Szychlinska M.A., Di Rosa M., Gastrogiovanni P., Mobasheri A. Osteoarthritis in the XXIst century: risk factors and behave iors that influence disease onset and progression. Int J Mol Sci. 2015;16(3):6093-6112. doi: 10.3390/ijms16036093.

3. Galushko E.A., Bolshakova T.Y., Vinogradova I.B., Ivanova O.N., Lesnyak O.M., Menshikova L.V. et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). Nauchno-prakticheskaya revmatologiya = RheumatologyScience and Practice. 2009;47(1):11-17. (In Russ.) doi: 10.14412/19954484-2009-136.

4. Balabanova R.M., Dubinina T.V. Five-year (2013-2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2019;13(4):11-17. (In Russ.) doi: 10.14412/19967012-2019-4-11-17.

5. Cleveland RJ., Nelson A.E., Callahan L.F. Knee and hip osteoarthritis as predictors of premature death: a review of the evidence. Clin Exp Rheumatol. 2019;37(S120):24-30. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934074.

6. Loeuille D., Chary-Valckenaere I., Champigneulle J., Rat A.C., Toussant F., Pinzano-Watrin A. et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum. 2005;52(11):3492-3501. doi: 10.1002/art.21373.

7. Sellman J., Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6(11):625-635. doi: 10.1038/nrrheum.2010.159.

8. Scanzello C.R. Role of low-grade inflammation in osteoarthritis. Curr Opin Rheumatol. 2017;29(1):79-85. doi: 10.1097/B0R.0000000000000353.

9. Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471-478. doi: 10.1097/BOR.0b013e328349c2b1.

10. Lila A.M., Alekseeva L.I., Telyshev K.A. Current approaches to osteoarthritis phenotyping. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):4-8. (In Russ.) doi: 10.14412/1996-7012-2019-2-4-8.

11. Farmer C., Fenu E., O’Flynn N., Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:i4843. doi: 10.1136/bmj.i4843.

12. Wesseling J., Welsing P.M., Bierma-Zeinstra S.M., Dekker J., Gorter KJ., Kloppenburg M. et al. Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: the CHECK (Cohort Hip and Cohort Knee) study. Rheumatology (Oxford). 2013;52(1):180-188. doi: 10.1093/rheumatology/kes288.

13. van Dijk G.M., Veenhof C., Schellevis F., Hulsmans H., Bakker J.P., Arwert H. et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMCMusculoskelet Disord. 2008;9:95. doi: 10.1186/1471-2474-9-95.

14. Alvarez C., Cleveland RJ., Schwartz T.A., Renner J.B., Murphy L.B., Jordan J.M. et al. Comorbid conditions and the transition among states of hip osteoarthritis and symptoms in a community-based study: a multi-state time-to-event model approach. Arthritis Res Ther. 2020;22(1):12. doi: 10.1186/s13075-020-2101-x.

15. Muckelt P.E., Roos E.M., Stokes M., McDonough S., Gr0nne D.T., Ewings S. et al. Comorbidities and their link with individual health status: A cross-sectional analysis of 23,892 people with knee and hip osteoarthritis from primary care. J Comorb. 2020;10:2235042X20920456. doi: 10.1177/2235042X20920456.

16. Naumov A.V., Alekseeva L.I. Management of patients with osteoarthritis and comorbidity in general medical practice: clinical guidelines. Moscow; 2016. (In Russ.) Available at: https://medvestnik.ru/apps/mv/assets/uploads/%D0%A1%D1%82%D0%B0%D1%82%D1%8C%D0%B8/REK-osteo2016.pdf.

17. Iannitti T., Lodi D., Palmieri B. Intra-Articular Injections for the Treatment of Osteoarthritis Focus on the Clinical Use of Hyaluronic Acid. Drugs R D. 2011;11(1):13-27. doi: 10.2165/11539760-000000000-00000.

18. Altman R.D., Manjoo A., Fierlinger A., Niazi F., Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321. doi: 10.1186/s12891-015-0775-z.

19. Brun P., Panfilo S., Daga Gordini D., Cortivo R., Abatangelo G. The effect of hyaluronan on CD44-mediated survival of normal and hydroxyl radicaldamaged chondrocytes. Osteoarthritis Cartilage. 2003;11(3):208-216. doi: 10.1016/S1063-4584(02)00352-7.

20. Brun P., Zavan B., Vindigni V., Schiavinato A., Pozzuoli A., Iacobellis C., Abatangelo G. In vitro response of osteoarthritic chondrocytes and fibroblast-like synoviocytes to a 500-730 kDa hyaluronan amide derivative. J Biomed Mater Res B Appl Biomater. 2012;100(8):2073-2081. doi: 10.1002/jbm.b.32771.

21. Williams J., Zhang J., Kang H., Ummadi V., Homandberg G.A. The effects of hyaluronic acid on fibronectin fragment mediated cartilage chondrolysis in skeletally mature rabbits. Osteoarthritis Cartilage. 2003;11(1):44-49. doi: 10.1053/joca.2002.0864.

22. Brandt K.D., Block J.A., Michalski J.P., Moreland L.W., Caldwell J.R., Lavin P.T. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res. 2001;(385):130-143. doi: 10.1097/00003086-200104000-00021.

23. Campo G.M., Avenoso A., Nastasi G., Micali A., Prestipino V., Vaccaro M. et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta. 2011;1812(9):1170-1181. doi: 10.1016/j.bbadis.2011.06.006.

24. Hiraoka N., Takahashi Y., Arai K., Honjo S., Nakawaga S., Tsuchida S. et al. Hyaluronan and intermittent hydrostatic pressure synergistically suppressed MMP-13 and Il-6 expressions in osteoblasts from OA subchondral bone. Osteoarthr Cartil. 2009;17(S1):97. doi: 10.1016/S1063-4584(09)60186-2.

25. Maheu E., Rannou F., Reginster J.Y Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):28-33. doi: 10.1016/j.semarthrit.2015.11.008.

26. Cooper C., Rannou F., Richette P., Bruyere O., Al-Daghri N., Altman R.D. et al. Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. Arthritis Care Res (Hoboken). 2017;69(9):1287-1296. doi: 10.1002/acr.23204.

27. Bellamy N., Campbell J., Robinson V., Gee T., Bourne R., Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2005;18(2):CD005321. doi: 10.1002/14651858.CD005321.

28. Bannuru R.R., Schmid C.H., Kent D.M., Vaysbrot E.E., Wong J.B., McAlindon T.E. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. doi: 10.7326/M14-1231.

29. Honvo G., Leclercq V., Geerinck A., Thomas T., Veronese N., Charles A. et al. Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):45-64. doi: 10.1007/s40266-019-00661-0.

30. Bannuru R.R., Natov N.S., Obadan I.E., Price L.L., Schmid C.H., McAlindon T.E. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and metaanalysis. Arthritis Rheum. 2009;61(12):1704-1711. doi: 10.1002/art.24925.

31. Bannuru R.R., Natov N.S., Dasi U.R., Schmid C.H., McAlindon T.E. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis-meta-analysis. Osteoarthritis Cartilage. 2011;19(6):611-619. doi: 10.1016/j.joca.2010.09.014.

32. Pena Ede L., Sala S., Rovira J.C., Schmidt R.F., Belmonte C. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. Pain. 2002;99(3):501-508. doi: 10.1016/S0304-3959(02)00260-9.

33. Sun S.F., Hsu C.W., Lin H.S., Liou I.H., Chen Y.H., Hung C.L. Comparison of single intra-articular injection of novel hyaluronan (HYA-JOINT Plus) with synvisc-one for knee osteoarthritis: a Randomized, Controlled, Double-Blind Trial of Efficacy and Safety. J Bone Joint Surg Am. 2017;99(6):462-471. doi: 10.2106/JBJS.16.00469.

34. Fallacara A., Baldini E., Manfredini S., Vertuani S. Hyaluronic Acid in the Third Millennium. Polymers (Basel). 2018;10(7):701. doi: 10.3390/polym10070701.

35. Nasonov E.L., Yakhno N.N., Karateev A.E., Alekseeva L.I., Barinov A.N., Barulin A.E. et al. General principles of treatment for musculoskeletal pain: interdisciplinary consensus. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-265. (In Russ.) doi: 10.14412/1995-4484-2016-247-265.

36. Belova K.Yu., Nazarova A.V. Strategy for the management of osteoarthritis in multimorbid patients: the balance of effectiveness and safety while choosing drug therapy. Meditsinskiy sovet = Medical Council. 2020;(11):164-176. (In Russ.) doi: 10.21518/2079-701X-2020-11-164-176.

37. Eliseeva L.N., Kartashova S.V., Blednova A.Yu., Semizarova I.V. Benefits of using artificial synovial fluids in gonarthrosis. RMZH. Meditsinskoe oboz-renie = RMJ. Medical Review. 2019;11(2):103-106. Available at: https://www.rmj.ru/articles/revmatologiya/Preimuschestva_ispolyzovaniya_pro-tektorov_sinovialynoy_ghidkosti_pri_gonartroze.